Biopharmaceutical Contract Manufacturing Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Global Biopharmaceutical Contract Manufacturing Market: By Manufacturing Process (Mammalian Based, Microbial Based, Insect Based, Plant Based, Yeast Based, Others), By Type Of Service (Formulation, Fill and Finish services,Cell Banking, Analytical Services, Process development, Others), By Molecule Type (Large Molecules, Small Molecules), By End-User (Biopharmaceutical Companies, Pharmaceutical Companies, Research Organizations, Others), and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Global biopharmaceutical contract manufacturing market size valued at USD 16.2 billion in 2021 and expected to reach USD 23.57 billion by 2028 at a CAGR of 5.5% during the forecast period 2022 to 2028. Biopharmaceuticals are also known as biologics. Biopharmaceutical products are pharmaceutical drugs that are synthesized, processed, or extracted from biological sources. Biopharmaceuticals include vaccines, blood products, recombinant therapeutic proteins, allergens, gene therapies, tissues and living cells used in cell therapy. Many companies outsource the manufacturing of biopharmaceuticals due to lack of manufacturing capabilities or in order to reduce the cost of manufacture process.Contract manufacturing organizations offer a wide range of services such as cell line development, process optimization, fermentation biotechnology, analytical characterization, cGMP manufacturing, and validation in each stage of clinical development and commercialization. Furthermore, to meet demand for biological products, companies are outsourcing the biopharmaceutical manufacturing to various contract manufacturing companies. However, high cost associated with manufacture and stringent regulatory requirements are expected to hamper the growth of biopharmaceutical contract manufacturing market. The market is highly competitive where the speed to market is imperative along with efficient process and low costs. Biopharmaceutical contract manufacturing services providers are increasing their service offerings such as formulation, production and analytical services apart from conventional services to provide complete support for biopharmaceutical companies. Cost considerations and quick services are expected continue to drive the outsourcing of global biopharmaceutical contract manufacturing market. In May 2017, Lonza Group Ltd. acquired cell and gene contract manufacturer PharmaCell B.V., this acquisition broadens Lonza’s capabilities in Europe region. Companies expanding the manufacturing facilities to increase market share. For instance, In May 2017, Boehringer Ingelheim GmbH started a new manufacturing facility in China to increase their manufacturing capacity. Through this facility company’s manufacturing capacity will increase by one-third.

Biopharmaceutical Contract Manufacturing Market

MARKET SUMMARY
-
5.50% CAGR
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 5.5%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Biopharmaceutical Contract Manufacturing Market

  • The report on global Biopharmaceutical Contract Manufacturing Market gives historical, current, and future market sizes (US$ Bn) on the basis of manufacturing process, type of service, molecule type, end users and geography.
  • Biopharmaceutical Contract Manufacturing Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa
Key Players
  • Lonza Group Ltd. (Switzerland)
  • Boehringer Ingelheim GmbH (Germany)
  • Charles River Laboratories, Inc. (U.S)
  • Novartis AG (Switzerland)
  • WuXi AppTec Group (China)
Dynamics

Biopharmaceutical Contract Manufacturing Market

Biopharmaceutical contract manufacturing market is mainly driven by increase in investment of the pharma and biotechnological companies to develop and commercialize the biotechnological products. In addition, high revenue generation of blockbuster biological drugs such as humira, rituxan, lantus, avastin, herceptin and remicade are gaining traction from many biologicsmanufacturers. Advancements in the biotechnology such as recombinant DNA technologies and targeted drug therapies are expected to bolster the biopharmaceutical contract manufacturing market over the forecast period.


North-America got significant share

Biopharmaceutical Contract Manufacturing Market

Geographically global biopharmaceutical contract manufacturing market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America and Europe are expected to be leading in biopharmaceutical contract manufacturing owing to increased approvals of biosimilars and increase in biopharmaceutical research organization which are lack of manufacturing facilities. In Asia-Pacific region, emerging countries such as China and India expected to grow at a rapid rate owing to low cost of manufacturing. Development of biologics pipeline by domestic companies expected to drive the growth of biopharmaceutical contract manufacturing in China.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share and forecast
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Biopharmaceutical Contract Manufacturing Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • Lonza Group Ltd. (Switzerland)
  • Boehringer Ingelheim GmbH (Germany)
  • Charles River Laboratories, Inc. (U.S)
  • Novartis AG (Switzerland)
  • WuXi AppTec Group (China)
  • Rentschler Biotechnologie GmbH (Germany)
  • Fujifilm Holdings Corporation (Japan)
  • Celonic AG (Switzerland)
  • BIOMEVA GmbH (Germany)
  • ProBioGen AG (Germany)

Description

Global biopharmaceutical contract manufacturing market size valued at USD 16.2 billion in 2021 and expected to reach USD 23.57 billion by 2028 at a CAGR of 5.5% during the forecast period 2022 to 2028. Biopharmaceuticals are also known as biologics. Biopharmaceutical products are pharmaceutical drugs that are synthesized, processed, or extracted from biological sources. Biopharmaceuticals include vaccines, blood products, recombinant therapeutic proteins, allergens, gene therapies, tissues and living cells used in cell therapy. Many companies outsource the manufacturing of biopharmaceuticals due to lack of manufacturing capabilities or in order to reduce the cost of manufacture process.Contract manufacturing organizations offer a wide range of services such as cell line development, process optimization, fermentation biotechnology, analytical characterization, cGMP manufacturing, and validation in each stage of clinical development and commercialization. Furthermore, to meet demand for biological products, companies are outsourcing the biopharmaceutical manufacturing to various contract manufacturing companies. However, high cost associated with manufacture and stringent regulatory requirements are expected to hamper the growth of biopharmaceutical contract manufacturing market. The market is highly competitive where the speed to market is imperative along with efficient process and low costs. Biopharmaceutical contract manufacturing services providers are increasing their service offerings such as formulation, production and analytical services apart from conventional services to provide complete support for biopharmaceutical companies. Cost considerations and quick services are expected continue to drive the outsourcing of global biopharmaceutical contract manufacturing market. In May 2017, Lonza Group Ltd. acquired cell and gene contract manufacturer PharmaCell B.V., this acquisition broadens Lonza’s capabilities in Europe region. Companies expanding the manufacturing facilities to increase market share. For instance, In May 2017, Boehringer Ingelheim GmbH started a new manufacturing facility in China to increase their manufacturing capacity. Through this facility company’s manufacturing capacity will increase by one-third.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX